Journal: BioMed Research International

Article Title: Papain Ameliorates the MPAs Formation-Mediated Activation of Monocytes by Inhibiting Cox-2 Expression via Regulating the MAPKs and PI3K/Akt Signal Pathway

doi: 10.1155/2018/3632084

Figure Lengend Snippet: Effect of papain on the formation of monocyte-platelet aggregates and monocytes activation. (a) Gating strategy for the quantification of MPA subsets in the coculture system of THP-1 cells and activated platelets by flow cytometry (FCM). MPAs was evaluated by expression of CD14 and CD41. CD14 + cells suggested being monocytes, and activated platelet was identified by CD41 expression. (b) Surface marker of monocyte activation was measured by FCM detection. Activated monocytes were stained with CD11b. (c) Results of quantitative analysis of CD14 and CD41 as well as CD11b positive cells in different concentrations of papain groups. K-S test showed that data were normal distribution in all groups (P>0.05). ∗ indicates thrombin-treated group versus control group. # indicates papain and thrombin-treated group versus single thrombin-treated group. ∗∗ p<0.01, ## p<0.01.

Article Snippet: For the measurements of monocyte-platelet aggregates (MPAs), the mixture in each group was incubated with CD14-PE antibodies (rabbit anti-human monoclonal antibody, Bioss), CD41-APC antibodies (mouse anti-human monoclonal antibody, eBioscience), and isotype matched controls for 20 mins at room temperature.

Techniques: Activation Assay, Flow Cytometry, Expressing, Marker, Staining

Journal: BioMed Research International

Article Title: Papain Ameliorates the MPAs Formation-Mediated Activation of Monocytes by Inhibiting Cox-2 Expression via Regulating the MAPKs and PI3K/Akt Signal Pathway

doi: 10.1155/2018/3632084

Figure Lengend Snippet: Impact of TNF- α on the protective effect of papain on MPAs formation and monocytes activation. (a) Gating strategy for the quantification of MPA subsets in the coculture system of THP-1 cells and activated platelets by flow cytometry (FCM). MPAs were evaluated by expression of CD14 and CD41. CD14 + cells suggested being monocytes, and activated platelet was identified by CD41 expression. (b) Surface marker of monocyte activation was measured by FCM detection. Activated monocytes were stained with CD11b. (c) Results of quantitative analysis of CD14 and CD41 as well as CD11b positive cells in control and thrombin, papain, NS-398 and TNF- α -treated groups. K-S test showed that data were in normal distribution in all groups (P>0.05). ∗ indicates thrombin-treated group versus control group. # indicates papain and thrombin-treated or NS-398-treated groups versus single thrombin-only-treated group. ∧ indicates papain+TNF- α -treated group versus papain or NS-398-treated groups. ∗∗ p<0.01, ## p<0.01, ∧∧p<0.01.

Article Snippet: For the measurements of monocyte-platelet aggregates (MPAs), the mixture in each group was incubated with CD14-PE antibodies (rabbit anti-human monoclonal antibody, Bioss), CD41-APC antibodies (mouse anti-human monoclonal antibody, eBioscience), and isotype matched controls for 20 mins at room temperature.

Techniques: Activation Assay, Flow Cytometry, Expressing, Marker, Staining

Journal: Atherosclerosis Plus

Article Title: Coronary atherosclerosis severity is closely associated with decreased GLP-1R positivity among CD16 + pro-inflammatory and patrolling monocyte subsets

doi: 10.1016/j.athplu.2021.10.001

Figure Lengend Snippet: Severe atherosclerosis is associated with increased proportions of intermediate (CD14+/CD16+ IMM) and non-classical (CD14-/CD16+ NC) monocytes and decreased frequency of GLP-1R positivity in these subsets. (A) Proportions of classical (CD14+/CD16+ CM), intermediate (CD14+/CD16+ IMM) and non-classical (CD14-/CD16 + NCM) subsets in total circulating monocyte amount of healthy controls (grey bars, n = 13) and patients with severe atherosclerosis (black bars, n = 10). ( B ) Frequency of monocytes expressing GLP-1R among different monocyte subsets in healthy controls (grey bars, n = 13) and patients with severe atherosclerosis (black bars, n = 10). Data are means ± SE.

Article Snippet: Briefly, blood was treated with human Fc-Receptor blocking solution (Biolegend, San Diego, CA), and subsequently stained with detection antibodies: anti human CD14 (Biogems, Westlake Village, CA); anti human CD16 (Biolegend, San Diego, CA); and either anti GLP-1R or mouse IgG2b isotype control (R&D Systems Minneapolis, MN).

Techniques: Expressing